VANCOUVER, BC / ACCESSWIRE / September 7, 2017 / CVR Medical Corp. (TSX.V:CVM.V) (FRANKFURT: B3BN) (OTCQB: CRRVF) (“CVR Medical“) advisory staff member Dr. Phillip J. Bendick, PhD, has released a summarized report on data from the tertiary clinical trials for the “Carotid Stenotic Scan (CSS)” device at Thomas Jefferson University (see press release dated June 29th, 2017). His report views initial evaluations as successful, and confirms the device’s value and efficiency.
Dr. Bendick’s report reviews the most pertinent features of the data collected from these first trials. “From a clinical standpoint […] the most important point is likely that the CSS, in a statistical sense, is very specific,” he states. Nearly all of the tested patients that had carotid artery stenosis were identified without an “overread,” an important measure which allows doctors to recommend steps for further care with confidence.
“From a development standpoint […] the greatest value of this latest data is the guidance it has provided in signal analysis.” Dr. Bendick notes that CVR will derive substantial benefit from the device’s ability to separate and use only high quality sub-sonic sound during application. This ensures that background noise that could otherwise skew results will not be confused as signals for narrowing arteries with higher pressure. “Going forward, this ability […] should improve even more the accuracy of the CSS to categorize a patient’s disease severity,” he concludes.
CVR CEO Peter Bakema, speaking on its release, expressed excitement for the indications of the report. “Internally, in discussions with our engineering and scientific development teams, indications are that we expect the device to improve markedly above the 85% sensitivity level. This, coupled with the expansion of trials for a larger sample size, continues to put us in position for a successful submission to the FDA.”
For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com
About CVR Medical
CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the “Joint Venture”). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.
For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888